{"schema_version":"1.0","type":"article","title":"當 ADC 走進自體免疫：不是殺得更狠，而是調得更準","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.md","lang":"zh-Hant","date":"2026-07-18","publish_at":"2026-07-18T20:00:00+08:00","updated_at":"2026-07-18","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","ADC","自體免疫疾病","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","免疫調節","類風濕性關節炎","生技投資"],"summary":"自體免疫 ADC 的價值不在把腫瘤細胞毒 payload 搬到免疫細胞，而在把 glucocorticoid、ASO、siRNA 等強效免疫調節作用定向送到真正需要干預的細胞；LFD-200 的早期人體訊號，是這條路第一次重要的機制驗證。","key_points":[],"facts":[],"sections":["01｜自體免疫治療，正在從壓制發炎走向重塑免疫","02｜自體免疫 ADC 有兩條路：清除細胞，或調節細胞","03｜LFD-200：自體免疫 ADC 的第一個重要訊號","04｜自體免疫 ADC 的位置：介於生物製劑與細胞治療之間","05｜自體免疫 ADC 不是換適應症，而是換一套開發規則","ADC 的下一個邊界，可能不是更強殺傷，而是更準免疫調節","參考資料"],"references":[{"title":"[Drugnews Dcard 原文]","source":"","date":"","url":"https://www.dcard.tw/@drugnews/post/261839370"},{"title":"[Lifordi Immunotherapeutics：LFD-200 技術介紹]","source":"","date":"","url":"https://www.lifordi.com/technology/lfd-200/"},{"title":"[Lifordi：EULAR 2026 Phase 1 初步資料新聞稿]","source":"","date":"","url":"https://www.biospace.com/press-releases/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026"},{"title":"[ClinicalTrials.gov：NCT07207954]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07207954"},{"title":"[Yaseen et al.：自體免疫疾病抗體藥物複合體綜述，PMID 40186891]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40186891/"},{"title":"[Zhou et al.：ADC 在非腫瘤疾病的應用綜述，PMID 40843358]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40843358/"},{"title":"[CD19 CAR-T 自體免疫疾病研究，Nature Medicine 2026]","source":"","date":"","url":"https://www.nature.com/articles/s41591-025-04185-6"},{"title":"[CD19 CAR-T 治療自體免疫疾病病例系列，PMID 38381673]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38381673/"}],"images":[{"alt":"ADC 從腫瘤的選擇性殺傷，延伸到自體免疫疾病的選擇性免疫調節","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-01.webp"},{"alt":"自體免疫 ADC 分成細胞清除與免疫調節兩條技術路線","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-02.webp"},{"alt":"LFD-200 將八個 glucocorticoid payload 定向送入 VISTA 陽性免疫細胞的作用機制與早期人體訊號","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-03.webp"},{"alt":"自體免疫 ADC 位於傳統生物製劑、小分子與重型細胞治療之間的商業定位","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-18）。當 ADC 走進自體免疫：不是殺得更狠，而是調得更準。https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-18-autoimmune-adc-lfd200-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}